Use of Analgesic Drugs in Renal Colic in Emergency Room

NCT ID: NCT03278652

Last Updated: 2017-09-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-19

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective non-interventional study on the use of analgesic drugs in renal colic in emergency rooms

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Colic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient with renal colic

Consumption of drugs for analgesic use

Intervention Type OTHER

* Regular assessment of pain
* Drug data will be collected (name, dosage, route of administration, time of delivery)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Consumption of drugs for analgesic use

* Regular assessment of pain
* Drug data will be collected (name, dosage, route of administration, time of delivery)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients older than 18 years old
* Suspicion of renal colic (pain in a lumbar pit radiating to the external genital organs, rapidly progressive onset, non-febrile)

Exclusion Criteria

* Shock
* Glasgow score less than 15
* Oxygen saturation less than 93% in ambient air
* Signs of intracranial hypertension (headache associated with vomiting)
* Suspicion of pneumothorax
* History of emphysema or chronic obstructive pulmonary disease
* Diving accident or suspicion of gas embolism
* Trauma of the face of interest in the area of application of the mask
* Abdominal gas distension
* Contraindication in Nonsteroidal anti-inflammatory drugs
* Pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rennes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Rennes

Rennes, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alexandre Tanneau, MD

Role: CONTACT

02.99.28.60.48

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alexandre Tanneau, MD

Role: primary

02.99.28.60.48

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

35RC16_3033_NEPHROPAIN

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Paracetamol and Pharmacogenetic
NCT01520792 COMPLETED PHASE1